What is 54Gene?
54Gene is a pioneering health technology company established in 2019 and headquartered in Lagos, Nigeria. Its core mission is to accelerate scientific discovery and enhance diagnostic and treatment outcomes across Africa and globally by focusing on African genomics. The company's work is crucial for unlocking the unique genetic insights within African populations, which have historically been underrepresented in global genomic research. Through its initiatives, 54Gene aims to bridge the gap in precision medicine and contribute to a more equitable healthcare landscape.
How much funding has 54Gene raised?
54Gene has raised a total of $44.5M across 3 funding rounds:
Angel/Seed
$4.5M
Series A
$15M
Series B
$25M
Angel/Seed (2019): $4.5M with participation from Y Combinator
Series A (2020): $15M led by Adjuvant Capital
Series B (2021): $25M supported by KdT Ventures, Adjuvant Capital, Cathay AfricInvest Innovation Fund, and Plexo Capital
Key Investors in 54Gene
Adjuvant Capital
Adjuvant Capital is an investment firm focused on advancing global health, likely specializing in ventures that address significant health challenges and improve patient outcomes through innovative solutions.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials. They often provide the first institutional check into companies, leading or co-leading pre-seed and seed funding rounds.
Cathay AfricInvest Innovation Fund
Cathay AfricInvest Innovation Fund is an investment vehicle dedicated to supporting innovative companies within Africa, likely focusing on technology and growth-stage businesses that have the potential for significant impact and scalability across the continent.
What's next for 54Gene?
With the recent major strategic investment, 54Gene is poised for significant expansion and further development of its genomic research capabilities. This capital infusion is expected to fuel advancements in its platform, enabling deeper exploration of African genetic diversity and the translation of these discoveries into tangible healthcare solutions. The company's focus on enterprise-level funding suggests a strategic push towards scaling its operations, forging new partnerships, and solidifying its position as a leader in genomic research within Africa and on the international stage.
See full 54Gene company page
